U.S., Oct. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07209163) titled 'Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma' on Sept. 30.
Brief Summary: In decades, the outcome of patients with peripherial T-cell lymphomas is dismal, especially in relapsed or refractory population. After failure to the frontline treatment, patients have limited treatment options and elderly population usually have no chance to undergo transplantation due to age or comorbidity, etc. EZH2 inhibitor like Tazemetostat or SHR 2554 has been demonstrated its anti-tumor activity in PTCL either alone or in combination with other targeted agents.
This study aims to explore the efficacy and ...